CENTRALISED LABORATORY NETWORK – SCI & TECH

News: India joins Centralised Laboratory Network (CLN) for testing vaccines

 

What's in the news?

       India has joined the Centralized Laboratory Network (CLN) which currently has 15 partner facilities in 13 countries that works to test vaccines which can be used during pandemic, epidemic disease outbreak.

 

Centralised Laboratory Network:

       CLN is a part of the Coalition for Epidemic Preparedness Innovations (CEPI) and the Network is the largest global group which has standardized methods and materials for testing.

 

Members:

       The laboratories initially selected for this vaccine-assessment network are: Nexelis (Canada) and Public Health England (PHE, UK), VisMederi Srl (Italy), Viroclinics-DDL (The Netherlands), icddr,b (formerly International Centre for Diarrhoeal Disease Research, Bangladesh), and Translational Health Sciences and Technological Institute (THSTI, India).

       The new members of the CLN now are Indian Council of Medical Research-National Institute of Virology (ICMR-NIV), Institute Pasteur de Dakar (IPD) (Senegal), KAVI Institute of Clinical Research (KAVI ICR) & University of Nairobi Institute of Tropical and Infectious Diseases (UNITID) (Kenya), Synexa Life Sciences (South Africa) and Uganda Virus Research Institute (UVRI) (Uganda).

 

CEPI:

       CEPI is an innovative partnership between public, private, philanthropic, and civil organizations, launched at Davos in 2017, to develop vaccines to stop future epidemics.

       The Department of Biotechnology, Ministry of Science & Technology is implementing the Ind-CEPI mission titled ‘India Centric Epidemic Preparedness through Rapid Vaccine Development: Supporting Indian Vaccine Development Aligned with the Global Initiative of the Coalition for Epidemic Preparedness Innovations (CEPI)’.

 

Aim:

  1. To identify the most promising vaccine candidates rapidly and accurately against emerging infectious diseases
  2. To strengthen the development of vaccines for the diseases of epidemic potential in India.
  3. To build coordinated preparedness in the Indian public health system and vaccine industry to address existing and emerging infectious threats in India.